CJC-1295 without DAC
CJC-1295 without DAC is a short-acting GHRH analog designed for research requiring rapid onset and precise timing of growth hormone release.
Key Research Points:
Studied for pulsatile growth hormone stimulation
Short half-life allows controlled research dosing schedules
Commonly researched alongside GHRPs in laboratory protocols
Explored in metabolism, recovery, and body composition studies
Intended strictly for research purposes
CJC-1295 (no DAC) is a modified GHRH analog (tetrasubstituted 29-amino acid peptide) that stimulates pulsatile GH release from the pituitary. Human studies demonstrate sustained, dose-dependent increases in both GH and IGF-1 with subcutaneous administration. Ipamorelin is a pentapeptide GH secretagogue with a half-life of approximately 1.5–2.5 hours that elicits a rapid GH pulse peaking around 40 minutes post-dose. Importantly, Ipamorelin selectively increases GH without affecting ACTH, cortisol, or prolactin levels. When combined, these peptides may produce synergistic GH release by acting on complementary receptor pathways.